SEC Filings | Aligos Therapeutics

Filing date	Description	Form	View
Nov 22, 2023	CORRESP	CORRESP	0001193125-23-282242.pdf 0001193125-23-282242.rtf 0001193125-23-282242.xls View HTML
Jun 02, 2023	DEFR14A	DEFR14A	0001193125-23-159828.pdf 0001193125-23-159828.rtf View HTML
Aug 26, 2020	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	0000950123-20-009341.pdf 0000950123-20-009341.rtf 0000950123-20-009341.xls View HTML
Jun 04, 2021	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	0000950123-21-007570.pdf 0000950123-21-007570.rtf 0000950123-21-007570.xls View HTML
Oct 15, 2020	EFFECT	EFFECT	9999999995-20-002863.xls View HTML
Jun 30, 2021	EFFECT	EFFECT	9999999995-21-002615.pdf 9999999995-21-002615.rtf 9999999995-21-002615.xls View HTML
Nov 19, 2021	EFFECT	EFFECT	9999999995-21-004423.pdf 9999999995-21-004423.rtf 9999999995-21-004423.xls View HTML
Nov 27, 2023	EFFECT	EFFECT	9999999995-23-003451.pdf 9999999995-23-003451.rtf 9999999995-23-003451.xls View HTML
Oct 22, 2020	Filing by person(s) reporting owned shares of common stock in a public company >5%	SC 13D	0001193125-20-274431.pdf 0001193125-20-274431.rtf 0001193125-20-274431.xls View HTML
Oct 30, 2020	Filing by person(s) reporting owned shares of common stock in a public company >5%	SC 13D	0001193125-20-282616.pdf 0001193125-20-282616.rtf 0001193125-20-282616.xls View HTML

Data provided by Kaleidoscope.